Context:

Lung cancer treatment has evolved with clearer distinctions between small-cell (SCLC) and non-small cell (NSCLC) forms, guiding choices from surgery to chemotherapy, radiation, targeted therapies, and immunotherapies. Biomarker testing is emphasized to tailor therapies to mutations, boosting outcomes as survival improves, with a 26% rise in five-year survival over five years. Surgical options exist mainly for early NSCLC, while SCLC relies more on non-surgical approaches. Radiation, chemotherapy, and emerging targeted and immune-based treatments expand options based on cancer subtype and stage. The outlook centers on personalized care, combination strategies, and ongoing mental health support for patients.

Dive Deeper:

• SCLC is rarely treated with surgery, whereas NSCLC may involve surgical resection (e.g., pneumonectomy, lobectomy, segmental resection, or wedge resection) depending on tumor size, location, and lung function, with minimally invasive techniques offering quicker recovery.

• Chemotherapy remains a cornerstone across NSCLC and SCLC, often used with radiation or targeted therapy, and includes regimens with drugs such as carboplatin, cisplatin, paclitaxel, pemetrexed, and others; side effects commonly include hair loss, nausea, fatigue, and infection risk.

• Radiation therapy can be used alone or with chemotherapy to treat earlier-stage disease or relieve symptoms in advanced cases, delivered via external beam methods like IMRT or SBRT, with potential side effects including fatigue, nausea, and lung irritation.

• Targeted therapies attack specific gene mutations (e.g., EGFR, ALK, ROS1, HER2, KRAS, MET, RET) and tend to have different, often milder, side effects than chemotherapy; effectiveness hinges on identifying actionable mutations through biomarker testing.

• Common mutations and corresponding targeted options include EGFR inhibitors (e.g., osimertinib), ALK inhibitors (e.g., alectinib), ROS1 inhibitors (e.g., entrectinib), HER2-directed agents (e.g., trastuzumab deruxtecan), and KRAS G12C inhibitors (e.g., sotorasib), reflecting growing precision medicine.

• Immunotherapy uses PD-1/PD-L1 inhibitors (e.g., pembrolizumab, nivolumab, atezolizumab) and CTLA-4 inhibitors in various combinations, with biomarker testing guiding likelihood of response and potential immune-related side effects.

• Antibody-drug conjugates and Bispecific T cell engager therapies represent newer approaches, combining targeted delivery with immune activation, and may be chosen when cancers recur or spread, though their side effects can resemble chemotherapy or provoke immune-related reactions.